Market capitalization | $604.46m |
Enterprise Value | $567.44m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.10 |
P/S ratio (TTM) P/S ratio | 3.30 |
P/B ratio (TTM) P/B ratio | 8.16 |
Sales growth (TTM) Sales growth | -16.91% |
Turnover (TTM) Turnover | $183.23m |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
16 Analysts have issued a Travere Therapeutics Inc forecast:
16 Analysts have issued a Travere Therapeutics Inc forecast:
Mar '24 |
+/-
%
|
||
Net profit | -136 -136 |
58%
58%
|
|
Depreciation and amortization | 9.88 9.88 |
3%
3%
|
|
Share compensation | 9.76 9.76 |
29%
29%
|
|
Operating cash flow | -119 -119 |
47%
47%
|
|
Investments | 6.47 6.47 |
77%
77%
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -119 -119 |
46%
46%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Eric Dube |
Employees | 380 |
Founded | 2008 |
Website | www.travere.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.